Recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) in posterolateral lumbar spine fusion: complications in the elderly

被引:16
|
作者
Hoffmann, Martin F. [1 ]
Jones, Clifford B. [1 ]
Sietsema, Debra L. [1 ]
机构
[1] Grand Rapids Med Educ Partners, Grand Rapids, MI 49503 USA
关键词
CLINICAL ARTICLE; PERIOPERATIVE COMPLICATIONS; GRAFT; SURGERY; AGE; DECOMPRESSION; MORBIDITY; MORTALITY; ADULTS; COST;
D O I
10.1186/1749-799X-8-1
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Study design: Retrospective cohort study of 1430 patients undergoing lumbar spinal fusion from 2002 - 2009. Objective: The goal of this study was to compare and evaluate the number of complications requiring reoperation in elderly versus younger patients. Summary of background data: rhBMP-2 has been utilized off label for instrumented lumbar posterolateral fusions for many years. Many series have demonstrated predictable healing rates and reoperations. Varying complication rates in elderly patients have been reported. Materials and methods: All patients undergoing instrumented lumbar posterolateral fusion of <= 3 levels consenting to utilization of rhBMP-2 were retrospectively evaluated. Patient demographics, body mass index, comorbidities, number of levels, associated interbody fusion, and types of bone void filler were analyzed. The age of patients were divided into less than 65 and greater than or equal to 65 years. Complications related to the performed procedure were recorded. Results: After exclusions, 482 consecutive patients were evaluated with 42.1% males and 57.9% females. Average age was 62 years with 250 (51.9%) < 65 and 232 (48.1%) >= 65 years. Patients >= 65 years of age stayed longer (5.0 days) in the hospital than younger patients (4.5 days) (p=0.005). Complications requiring reoperation were: acute seroma formation requiring decompression 15/482, 3.1%, bone overgrowth 4/482, 0.8%, infection requiring debridement 11/482, 2.3%, and revision fusion for symptomatic nonunion 18/482, 3.7%. No significant differences in complications were diagnosed between the two age groups. Statistical differences were noted between the age groups for medical comorbidities and surgical procedures. Patients older than 65 years underwent longer fusions (2.1 versus 1.7 levels, p=0.001). Discussion: Despite being older and having more comorbidities, elderly patients have similar complication and reoperation rates compared to younger healthier patients undergoing instrumented lumbar decompression fusions with rhBMP-2.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Enhancement of posterolateral lumbar spine fusion using recombinant human bone morphogenetic protein-2 and mesenchymal stem cells delivered in fibrin glue
    Liu, Zunpeng
    Zhu, Yue
    Zhu, Haitao
    He, Xiaoning
    Liu, Xinchun
    JOURNAL OF BIOMATERIALS APPLICATIONS, 2016, 31 (04) : 477 - 487
  • [32] Evaluation of complications associated with off-label use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in pediatric orthopaedics
    Norbert Stiel
    Tim N. Hissnauer
    Martin Rupprecht
    Kornelia Babin
    Carsten W. Schlickewei
    Johannes M. Rueger
    Ralf Stuecker
    Alexander S. Spiro
    Journal of Materials Science: Materials in Medicine, 2016, 27
  • [33] Cyst-Like Osteolytic Formations in Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) Augmented Sheep Spinal Fusion
    Pan, Hsin Chuan
    Lee, Soonchul
    Ting, Kang
    Shen, Jia
    Wang, Chenchao
    Nguyen, Alan
    Berthiaume, Emily A.
    Zara, Janette N.
    Turner, A. Simon
    Seim, Howard B., III
    Kwak, Jin Hee
    Zhang, Xinli
    Soo, Chia
    AMERICAN JOURNAL OF PATHOLOGY, 2017, 187 (07): : 1485 - 1495
  • [34] Lateral lumbar interbody fusion - clinical outcomes, fusion rates and complications with recombinant human bone morphogenetic protein-2
    Morton, Matthew B. B.
    Wang, Yi Yuen
    Buckland, Aaron J. J.
    Oehme, David A. A.
    Malham, Gregory M. M.
    BRITISH JOURNAL OF NEUROSURGERY, 2025, 39 (01) : 71 - 77
  • [35] Bone apposition to titanium implants biocoated with recombinant human bone morphogenetic protein-2 (rhBMP-2). A pilot study in dogs
    Jürgen Becker
    Axel Kirsch
    Frank Schwarz
    Maria Chatzinikolaidou
    Daniel Rothamel
    Vojislav Lekovic
    Herbert Peter Jennissen
    Clinical Oral Investigations, 2006, 10 : 217 - 224
  • [36] Administration of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) and Chitosan Scaffold in calvarial bone defects in Wistar rats
    Sanjaya, I. Gusti Putu Hendra
    Maliawan, Sri
    Sudarsa, I. Wayan
    Mahadewa, Tjokorda Gde Bagus
    BALI MEDICAL JOURNAL, 2024, 13 (02) : 750 - 754
  • [37] De novo bone induction by recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillary sinus floor augmentation
    Boyne, PJ
    Lilly, LC
    Marx, RE
    Moy, PK
    Nevins, M
    Spagnoli, DB
    Triplett, RG
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2005, 63 (12) : 1693 - 1707
  • [38] RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2 IN SPINE SURGERY
    Hsu, Wellington K.
    JBJS REVIEWS, 2014, 2 (06)
  • [39] Formation of Painful Seroma and Edema After the Use of Recombinant Human Bone Morphogenetic Protein-2 in Posterolateral Lumbar Spine Fusions
    Garrett, Mark P.
    Kakarla, Udaya K.
    Porter, Randall W.
    Sonntag, Volker K. H.
    NEUROSURGERY, 2010, 66 (06) : 1044 - 1049
  • [40] The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers
    Glassman, Steven D.
    Dimar, John R., III
    Burkus, Kenneth
    Hardacker, James W.
    Pryor, Philip W.
    Boden, Scott D.
    Carreon, Leah Y.
    SPINE, 2007, 32 (15) : 1693 - 1698